Clinical trial
Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients With Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation
NCT05984199 is registered in ClinicalTrials.gov with Vor Biopharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients With Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation
- Lead sponsor
- Vor Biopharma
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- December 11, 2023
- Completion date
- May 28, 2025
- Enrollment
- 38 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.